Clinical Edge Journal Scan

No effect of initial glucocorticoid bridging on glucocorticoid use over time in RA


 

Key clinical point: In patients with newly diagnosed rheumatoid arthritis (RA), initial glucocorticoid bridging (GB) led to more rapid clinical improvements than non-bridging, without any apparent risk for increased glucocorticoid use after the intended bridging period.

Major finding: The risk of using glucocorticoids at 12 months was higher in the GB vs non-bridging group, but this risk reduced over time and was not significantly different at 18 and 24 months. The cumulative doses did not differ significantly between groups after the planned bridging schedule. Patients in the GB group showed more rapid improvements in the mean Disease Activity Score of 28 Joints during the first 6 months ( P < .001).

Study details: This individual patient data meta-analysis combined data from three randomized clinical trials and included 625 patients with newly diagnosed RA who received conventional synthetic disease-modifying antirheumatic drugs with (n = 252) or without (n = 373) initial GB.

Disclosures: This study did not declare any specific funding source. Some authors declared receiving consultancy or speaker honoraria, fees, or grants from or providing expert advice or testimony for or serving as chair for various sources.

Source: van Ouwerkerk L et al. Initial glucocorticoid bridging in rheumatoid arthritis: Does it affect glucocorticoid use over time? Ann Rheum Dis. 2023 (Aug 22). doi: 10.1136/ard-2023-224270

Recommended Reading

Patients with RA remain at higher risk for COVID-19-related adverse outcomes even in SARS-CoV-2 Omicron era
MDedge Rheumatology
Rheumatology trials seem vulnerable to unblinding: Report
MDedge Rheumatology
Slight weight gain, no blood pressure increase with low-dose steroids for RA
MDedge Rheumatology
Medicare announces 10 drugs targeted for price cuts in 2026
MDedge Rheumatology
ACR releases guideline for managing ILD in patients with rheumatic disease
MDedge Rheumatology
Commentary: Cardiovascular risk, anti-drug antibodies, and prednisolone in RA, September 2023
MDedge Rheumatology
Precision blood test for rheumatoid arthritis receives Medicare coverage
MDedge Rheumatology
Early glucocorticoid bridging in RA supported by meta-analysis, but concerns remain
MDedge Rheumatology
Weight gain and increased BP concerns should not deter low-dose glucocorticoid use in RA
MDedge Rheumatology
Tapering TNFi raises disease flare likelihood in patients with RA even in those in remission
MDedge Rheumatology